Legend Biotech Corporation announced the official opening and ribbon cutting of its new, research and development (R&D) facility in Philadelphia, Pennsylvania. The site features cutting-edge laboratories and collaborative workspaces designed to foster innovation and accelerate research programs across Legend's oncology and immunology portfolios. The Philadelphia R&D center expands Legend's American presence, which includes over 1,400 employees in the United States.
The site will employ approximately 55 full-time team members and complements Legend's existing R&D presence in Piscataway, New Jersey. Headquartered in Somerset, N.J., Legend also has manufacturing activities in Raritan and Morris Plains, N.J. Local officials, academic partners, patient advocacy groups, and members of the Philadelphia biotech community gathered with Legend Biotech leadership to celebrate the ribbon-cutting ceremony and tour the new facility. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson.
To date, CARVYKTI has been administered to over 9,000 patients with multiple myeloma at 132 treatment centers spanning 44 states across the U.S. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
